Colby Pharmaceutical Company is a privately held company that develops small molecule Oxidative Stress Modulator (OSM) drugs for treatment of prostate disease that includes prostate cancer (PCa). and gland enlargement or benign prostate hyperplasia (BPH), Colby is focused on the clinical development of its two lead drugs for two different stages of PCa. Colby’s lead drugs, CPC-100 and CPC-200, are potent therapeutics targeting two different cohorts of men with PCa. CPC-100 will enter a Phase I/IIa human clinical trial for men with recurrent Prostate Cancer, post-ADT (Androgen Deprivation Therapy) in 2008. CPC-200 will subsequently enter a Colby sponsored Phase l/lla clinical trial for men pre-ADT in 2009. These drugs have unique mechanisms of action for use either as stand-alone drugs or in combination with currently sold Standard of Care (SOC) PCa drugs.
Colby has identified four Prostate Cancer OSM drug candidates, each targeting and inhibiting modulating different oxidative stress generating pathways. The company is developing its OSM drugs for large existing PCa markets with unmet medical needs.
Colby has operations in Menlo Park, CA and Madison, WI. The Company is strategically affiliated with the University of Wisconsin-Madison's Paul P. Carbone Comprehensive Cancer Center, the Wisconsin Alumni Research Foundation and the Medical College of Wisconsin’s Free Radical Research Center. Colby has assembled a world-class team including clinical oncologists and pharmaceutical experts with the experience to bring these drugs through clinical development.
